Results 31 to 40 of about 1,569,733 (298)

Structural Studies and Structure Activity Relationships for Novel Computationally Designed Non-nucleoside Inhibitors and Their Interactions With HIV-1 Reverse Transcriptase

open access: yesFrontiers in Molecular Biosciences, 2022
Reverse transcriptase (RT) from the human immunodeficiency virus continues to be an attractive drug target for antiretroviral therapy. June 2022 will commemorate the 30th anniversary of the first Human Immunodeficiency Virus (HIV) RT crystal structure ...
Kathleen M. Frey   +8 more
doaj   +1 more source

Molecular monitoring of HIV-1 drug resistance in Ifakara HIV-1 Cohort, Tanzania [PDF]

open access: yes, 2013
HIV-1 resistance is one of the problems affecting success of antiretroviral therapy programmes worldwide. Many studies on efficacy of ART programmes, specifically on drug resistance, have been conducted in developed countries but not in developing ...
Masimba, Pax Jessey
core   +1 more source

In vitro and ex vivo inhibition of human telomerase by anti-HIV nucleoside reverse transcriptase inhibitors (NRTIs) but not by non-NRTIs.

open access: yesPLoS ONE, 2012
Telomerase is a specialized reverse transcriptase responsible for the de novo synthesis of telomeric DNA repeats. In addition to its established reverse transcriptase and terminal transferase activities, recent reports have revealed unexpected cellular ...
Kyle R Hukezalie   +3 more
doaj   +1 more source

Docking Study of HIV-1 Reverse Transcriptase (HIV-1 RT) with Well-Known Nucleoside Reverse Transcriptase Inhibitors (NRTIs) [PDF]

open access: yesJournal of Advanced Pharmacy Research
Objectives: The nucleic acid-binding cleft in HIV-1 reverse transcriptase (HIV-1 RT) is essential because of its interactions with the polymerase and RNase H active sites. Studying its binding sites for nucleoside reverse transcriptase inhibitors (NRTIs)
Roohallah Yousefi
doaj   +1 more source

HIV - recentes avanços na pesquisa de fármacos HIV - highlights in drug research

open access: yesQuímica Nova, 2008
The development of new antiretroviral drugs is a dynamic process that is continuously fueled by identification of new molecular targets and new compounds for know targets.
Wilson Cunico   +2 more
doaj   +1 more source

The proportion of drug-resistant mutations selected by the nucleoside reverse transcriptase inhibitors among adolescents and young adults.

open access: yes, 2023
The proportion of drug-resistant mutations selected by the nucleoside reverse transcriptase inhibitors among adolescents and young adults.
Godfrey Barabona (11339337)   +26 more
core   +1 more source

A Review of Electroanalytical Techniques for Determination of Anti-HIV Drugs

open access: yesInternational Journal of Electrochemistry, 2011
Until now after the human immunodeficiency virus (HIV) was discovered as the then tentative aetiological agent of acquired immune deficiency syndrome (AIDS), exactly 25 anti-HIV compounds have been formally approved for clinical use in the treatment of ...
Burçin Bozal   +2 more
doaj   +1 more source

The proportion of drug-resistant mutations selected by non-nucleoside reverse transcriptase inhibitors among adolescents and young adults.

open access: yes, 2023
The proportion of drug-resistant mutations selected by non-nucleoside reverse transcriptase inhibitors among adolescents and young adults.
Godfrey Barabona (11339337)   +26 more
core   +1 more source

Chemical structures of the studied non-nucleoside reverse transcriptase inhibitors.

open access: yes, 2015
Chemical structures of the studied non-nucleoside reverse transcriptase inhibitors.
Markus Hecht (757364)   +8 more
core   +1 more source

Inhibitors of human immunodeficiency virus type 1 reverse transcriptase target distinct phases of early reverse transcription

open access: yes, 2001
Early HIV-1 reverse transcription can be separated into initiation and elongation phases. Here we show, using PCR analysis of negative-strand strong-stop DNA [(-)ssDNA] synthesis in intact virus, that different reverse transcriptase (RT) inhibitors ...
Harrich, D.   +5 more
core   +1 more source

Home - About - Disclaimer - Privacy